Q-omics provides the consensus-scored OSTCP2 profile across patient tissues and cancer cell-line models. OSTCP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, OSTCP2 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, OSTCP2 RNA expression shows 8,322 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRP, and THYM as cancer lineages where OSTCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSTCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSTCP2 survival associations across molecular data types. OSTCP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSTCP2 RNA expression–survival associations across cancer types. High OSTCP2 expression shows unfavorable associations in UVM, LGG and ACC, but favorable associations in BLCA, READ and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for OSTCP2 RNA expression.
This table summarizes OSTCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OSTCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSTCP2 shows lower tumor expression in KIRP, KIRC and KICH and higher tumor expression in UCEC, STAD and CHOL. The KIRP box plot shows higher OSTCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.145, t-test p = .001).
This table shows molecular features associated with OSTCP2 in patient tissues and cancer cell lines. In patient samples, OSTCP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
